Author details

Full Name

William K Oh

Affiliation

ORCID

Career Start Year

1998

Papers

296

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37003085	Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.	Eur J Cancer	2023
35788726	Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.	Journal of Cancer Research and Clinical Oncology	2023
36519763	Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer.		2023
36494221	Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.	Eur Urol	2023
34363009	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.	Prostate Cancer Prostatic Dis	2022
35657341	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.	JNCI Cancer Spectr	2022
35450732	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.	Eur Urol	2022
35960456	Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.	Discover Oncology	2022
35579581	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.	Clin Adv Hematol Oncol	2022
35579580	Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.	Clinical Advances in Hematology and Oncology	2022
35579577	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.	Clin Adv Hematol Oncol	2022
35696627	Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer.	JCO clinical cancer informatics	2022
35440417	Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].	Eur Urol	2022
35438782	Phase II Clinical and Translational Study of Everolimus Â± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.	Oncologist	2022
35551363	Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?	JAMA Oncology	2022
35984843	Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience.	PLoS One	2022
35298662	Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.	Oncologist	2022
35295598	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients.	Front Med (Lausanne)	2022
34460965	Consensus report: Definition and interpretation of remission in type 2 diabetes.	Diabetic Medicine	2022
34459898	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.	Journal of Clinical Endocrinology and Metabolism	2022
35239955	Global DNA methylation of WTC prostate cancer tissues show signature differences compared to non-exposed cases.	Carcinogenesis	2022
35006484	Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.	Breast Cancer Res Treat	2022
34646777	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.	Frontiers in Oncology	2021
34011488	Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?		2021
33531652	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.	Prostate Cancer and Prostatic Diseases	2021
34048378	A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 Pandemic.	Quality Management in Health Care	2021
33837006	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.	Clin Cancer Res	2021
34208521	Prostate Cancer Dormancy and Reactivation in Bone Marrow.	Journal of Clinical Medicine	2021
33829580	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.	Oncologist	2021
32960679	Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.	Journal of Urology	2021
32960678	Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.	J Urol	2021
33417323	Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.	Am J Clin Oncol	2021
34462270	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.	Diabetes Care	2021
34458934	Consensus report: definition and interpretation of remission in type 2 diabetes.	Diabetologia	2021
34722126	Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?		2021
33109676	Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records.	BMJ Open	2020
32313142	Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial.	Prostate Cancer and Prostatic Diseases	2020
32243894	COVID-19 infection in cancer patients: early observations and unanswered questions.	Annals of Oncology	2020
32001144	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.	Eur Urol	2020
32462179	Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.	Blood	2020
34258585	Accelerating precision medicine in metastatic prostate cancer.	Nat Cancer	2020
32767764	Treatment of muscle-invasive and advanced bladder cancer in 2020.	Ca-A Cancer Journal for Clinicians	2020
32760849	Lacrimal sac adenocarcinoma managed with androgen deprivation.	American Journal of Ophthalmology Case Reports	2020
33112397	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.	JAMA Netw Open	2020
27141017	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.	Ann Oncol	2019
31272788	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.		2019
31221798	Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade.	Molecular Cancer Research	2019
31161846	The evolving landscape of immunotherapy in advanced prostate cancer.	Immunotherapy	2019
31200951	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.	Eur Urol	2019
27898584	Prostate cancer characteristics in the World Trade Center cohort, 2002-2013.	European Journal of Cancer Prevention	2018